IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Artificial Intelligence In Drug Discovery And Development

Omkar Sanjay Khavare[1] , Tejashree S. Khamkar[2] , Harshvardhan Gajanan Jadhav[3] , Aman Noushad Shirale[4] , Omkar Milind Jadhav[5]

[1,3,4,5]Department of pharmacy ,Ashokrao Mane College Of Pharmacy ,Peth Vadgaon /Shivaji University 416112,Maharashtra,India

[2]Department Of Pharmaceutical Chemistry, Assistant Professor,Ashokrao Mane College Of Pharmacy ,Peth Vadgaon /Shivaji University 416112,Maharashtra,India

Abstract:

By speeding up research, cutting expenses, and opening up new treatment approaches, artificial intelligence (AI) is revolutionizing the field of drug discovery and development. To find pharmacological targets, create lead compounds, forecast pharmacokinetics and toxicity, and improve clinical study designs, AI-driven methods make use of enormous datasets from genomes, proteomics, metabolomics, clinical trials, and empirical data. Cloud computing and big data infrastructures facilitate scalable operations, while machine learning, deep learning, and natural language processing improve the effectiveness of virtual screening, de novo molecule creation, and structure–activity relationship modeling. From hit detection to regulatory filing, end-to-end innovation is made possible by combining AI with automation, robots, and high-throughput experimentation. Notwithstanding its potential, issues with data quality, interpretability, moral application, and regulatory approval of insights generated by AI still exist.

To fully realize AI's promise in precision and personalized medicines, interdisciplinary cooperation between academia, industry, and regulatory agencies is necessary, as are ongoing developments and explainable AI.

Keywords -Artificial intelligence (AI),Drug discovery and development,Precision medicine,Personalized medicine,Machine learning (ML),Deep learning (DL),Natural language processing (NLP),Big data,Cloud computing,Genomics, Proteomics,Metabolomics,Clinical trials,Virtual screening, De novo drug design,Structure–activity relationship (SAR) modeling, Pharmacokinetics prediction,Toxicity prediction,High-throughput screening (HTS),Automation and robotics, Data quality, Model interpretability,Explainable AI (XAI),Regulatory challenges,Ethical considerations, Interdisciplinary collaboration,Academia–industry partnerships

1.Introduction

The process of discovering and developing new drugs is lengthy, costly, and fraught with risk, with only a small percentage of potential molecules ultimately making it to the market[1]. Traditional methods—heavily dependent on trial-and-error evaluations, extensive laboratory work, and iterative refinements—typically necessitate over ten years and billions of dollars to yield a single effective treatment[2]. In recent times, the swift advancement of computational capabilities, the accessibility of large biomedical datasets, and improvements in algorithm development have created an optimal environment for the incorporation of Artificial Intelligence (AI) into pharmaceutical research.

AI comprises a range of techniques, such as machine learning, deep learning, and natural language processing, which allow computers to recognize intricate patterns and generate predictions from extensive datasets[3]. Within the realm of pharmaceuticals, AI is increasingly utilized at each stage of the research and development continuum: identifying and validating biological targets, designing innovative molecular frameworks, forecasting absorption–distribution–metabolism–excretion–toxicity (ADMET) profiles, and enhancing clinical trial design. By minimizing experimental demands and enhancing decision-making precision, AI holds the potential to hasten innovation, reduce development expenses, and boost the likelihood of successfully delivering new medications to patients[4].

Despite its revolutionary promise, the incorporation of AI into drug discovery faces numerous obstacles, including concerns about data quality, model interpretability, regulatory issues, and ethical dilemmas. This review seeks to offer a thorough overview of the existing landscape of AI in drug discovery and development, showcase significant case studies, address technical and practical limitations, and delineate future avenues for leveraging AI as a formidable asset in pharmaceutical science[5].

1.1Background on Traditional Drug Discovery

Drug discovery serves as the essential process through which new therapeutic agents are recognized, refined, and developed for clinical application[6]. Traditionally, this process has been predominantly linear and experimentation-heavy, starting with the identification of a biological target linked to a disease, followed by screening extensive chemical libraries to uncover "hits" with the desired biological effect. Promising hits undergo further refinement through lead optimization, wherein medicinal chemists alter chemical structures to enhance potency, selectivity, and physicochemical characteristics[7].

Once a lead compound satisfies fundamental safety and efficacy criteria, it advances to preclinical studies that include in vitro and in vivo assessments of pharmacokinetics, pharmacodynamics, and toxicity[8]. Candidates that clear these evaluations move forward to clinical trials, which are carried out in sequential phases to establish safety, dosage, and therapeutic effectiveness in humans[9]. Only after demonstrating acceptable risk–benefit ratios and fulfilling regulatory standards has this traditional route facilitated the discovery of life-saving medications; however, it remains time-consuming, expensive, and subject to high rates of failure. On average, bringing a single successful drug to market can take 10–15 years and cost billions of dollars. Many candidates falter in later stages due to insufficient efficacy, unexpected toxicity, or poor pharmacokinetics[8]. Additionally, the vast expanse of chemical space renders it impossible to experimentally assess every potential molecule, constraining the efficiency of hit identification and lead optimization.These challenges have heightened interest in computational tools and, more recently, AI to enhance and expedite the drug discovery process[10].

1.2Demand for AI in Pharmaceutical Research and Development

The traditional process of drug discovery and development is protracted, costly, and marked by significant failure rates[11]. Despite notable improvements in high-throughput screening, combinatorial chemistry, and robotic lab techniques, the likelihood of successfully converting a new chemical entity into a sanctioned treatment remains low[11]. Several elements underscore the necessity for Artificial Intelligence (AI) in contemporary pharmaceutical research:



Fig No -1 Demand of AI in pharamceutical research and development

1.3 Scope and Aims of the Review

Scope

- AI applications from initial research stages to post-approval processes, including:

- Target identification and validation

- Hit discovery and virtual screening

- Lead optimization and de novo molecular design

- Prediction of pharmacokinetic and toxicity profiles (ADMET)

- Design and oversight of preclinical and clinical studies

- Discusses the integration of AI with high-throughput screening, omics data, and big data analytics.

- Reviews significant case studies, emerging startups, and collaborations between industry and academia.

- Highlights regulatory, ethical, and technical aspects pertinent to pharmaceutical practices.

Objectives

- Summarize the current landscape of AI tools and algorithms employed in drug discovery.

-Analyze successful cases and key takeaways from AI-powered drug development initiatives.

-Recognize current obstacles such as data reliability, explainability, and validation standards.

-Investigate prospective paths forward, including interpretable AI, automation technologies, and tailored treatment options.

-Offer guidance for pharmacy students, researchers, and professionals on adopting AI responsibly and effectively within pharmaceutical research.

2. Overview of Artificial Intelligence in Healthcare.

Artificial Intelligence (AI) refers to computer systems designed to perform tasks that normally require human intelligence, such as learning, reasoning, problem-solving, and decision-making. Within the healthcare sector, AI has become a revolutionary technology, allowing for quicker data analysis, enhanced diagnostic precision, and more streamlined research and development activities[12].

2.1 Definitions and Key Concepts



Fig no -2 key concepts of AI

2.2 Evolution of AI Techniques

• Early Expert Systems (1970s–1990s): The MYCIN-type of expert system proved that one could develop rule-based reasoners for medical diagnosis.

• Machine Learning Era (2000s): Algorithms which could learn from data, for instance, decision-tree models and support vector machines, generate more flexible forms of prediction[12].

• Deep Learning and Big Data (2010s and going): With the advent of cloud computing, deep neural nets (convolutional and recurrent) can process huge arrays of data, such as medical images, genomics, and EHRs[12].

2.3 AI VERSUS CONVENTIONAL COMPUTATIONAL APPROACHES

Computational methods have always served drug discovery in pharmaceutical sciences. There are such as molecular docking, quantitative structure-activity relation modeling, and rule-based algorithms. While these techniques are still useful and valued, AI has several advantages that simply cannot be realized with conventional approaches[13].

1]Nature of Learning

• Conventional computational methods work on precisely defined rules, equations, or heuristics formulated from human knowledge (force fields, linear regression).

• AI methods, primarily ML and DL, learn patterns automatically from data so that they adapt when new data becomes available[12].

2]Handling Data Complexity

• Traditional modeling techniques perform well when presented with relatively small, structured datasets with simple relationships.

• AI can analyze extremely large, heterogeneous, and high-dimensional data sets such as genomic sequences, medical images, chemical graphs, and clinical records[11].

3]Predictive Accuracy & Generalization

• Rule-based or statistical methods might lose accuracy if the systems are getting complex and non-linearly related[10].

• AI algorithms help deep neural networks to recognize non-linear, hierarchical relationships better and thus predict better in things like ADMET predictions or de novo molecule designs[11].

4]Feature Engineering

•Classical models require a lot of manual intervention to select and evaluate salient features and need well-defined descriptors from domain experts[12].

5] Automated Feature Extraction

• From raw data, features are extracted automatically by artificial intelligence (e.g., DL's convolutional layers determine useful patterns)[13].

6]Flexibility and Scalability

• A conventional model may have to be redesigned by changing the equations or parameter values during the update.

• AI systems can be retrained with new data, hence providing more scalability in a fast-evolving research environment[14].

7]Limitations and Considerations

• AI models require large, top-quality datasets and can behave as 'black boxes,' making inference difficult.

• Traditional methods may be less accurate but usually are transparent and easier to validate, often requiring fewer computing resources[13].

8]The Synergy Between Different Approaches

Instead of completely supplanting older methods, AI is often at its most effective when combined with conventional computational chemistry and bioinformatics techniques. Hybrid approaches, such as AI-driven docking or ML-aided QSAR, give researchers an opportunity to exploit the merits of both[14].

3.Applications of AI Across Drug Discovery Stages

3.1 Target Identification and Validation

Target identification and validation is the most essential step of drug discovery. A target may be a gene, protein, receptor, enzyme, or signaling pathway whose modulation is expected to produce a therapeutic effect. There are many traditional ways to discover targets, including literature mining, genetics, biochemical assays, and animal models[15]. However, although these approaches are common, they also can be time and labor-intensive while remaining limited by their dependence on availability of experimental data. Artificial intelligence is now transforming this stage by giving researchers the ability to integrate and analyze multiple large, variable datasets so as to identify promising targets at a much faster pace and with better accuracy[14].

Role of AI in Target Identification

Data Integration: It integrates genomics, transcriptomics, proteomics, metabolomics, clinical studies, and biomedical literature arising from several disciplines to find associations between molecular entities and diseases[15].

Pattern Recognition: Machine learning models can extract weak correlations between genetic variation and disease phenotype which usually escape a conventional statistical analysis.

• Knowledge Graphs and Network Analysis: AI-based network models allow the mapping of relationships among proteins, pathways, and diseases, thereby aiding investigators in discovering new therapeutic targets[16].

• Natural Language Processing (NLP): The text-mining tools scan through millions of research articles, patents, and clinical trial reports seeking insights into potential targets[12].

Role of AI in Target Validation

• **Predictive Modeling:** AI predicts whether modulating a candidate target is actually going to bring about some worthwhile therapeutic effect with little off-target effect.

• **Analysis of Experimental Data**: Deep learning may be utilized to analyze high-content screening images or multi-omics datasets related to targets to validate their biological relevance.

• **CRISPR and Gene-Editing Data:** AI helps interpret CRISPR screening results to validate genes that are involved in disease progression.

• **Biomarker Discovery:** AI detects biomarkers that verify the correlation between target modulation and clinical outcomes[17].

Advantages

• In preparing lists, combining multi-dimensional data sources improves the predictions.

• It reduces cost and time in experiments because it only prioritizes molecules that really have a chance of being confirmed in the laboratory.

Challenges

• Key to predictions is good-quality data: if data is noisy and biased, so will be the predictions.

• Models must be transparent and explainable for regulators to accept them.

• Integration of AI predictions with wet-lab experiments is still needed to verify biological relevance.

3.2 Hit Identification & Virtual Screening

After a therapeutic target has been identified and validated, the next step is to find small molecules or hits capable of interacting with that target. Traditionally, this step concerns high-throughput screening of huge chemical libraries in wet-lab assays[18]. While effective, HTS is costly, time-consuming and generally produces very few, if any, candidates with real prospects.

Therefore, AI-Powered VS and related methods strongly complement and compete with classical approaches[18].

Role of AI in Touching Hit Identification

• **Data-Driven Prioritization:** ML models could learn from past screening results and prioritize compounds with the highest probability of being active against a target.

• **Ligand-Based Virtual Screening:** AI algorithms predict biological activity from molecular descriptors or fingerprints and rank those compounds in huge libraries without ever physically testing them.

• **Structure-Based Screening:** Deep learning is also useful in docking by predicting binding affinities and refining docking poses between the ligands and the protein targets.

•**Chemical Space Exploration:** Generative models such as variationalautoencoders and GANs can propose new molecules that might bind to the target, extending the search beyond existing commercial libraries[19].

AI-Approach to Virtual Screening

• **QSAR with ML/DL:** Quantitative structure–activity relationship models using ML/DL algorithms designed to predict potency and selectivity for novel compounds.

• **Deep Docking:** It is an approach combining docking engines with deep learning to cut down on the number of molecules for which computationally expensive scoring functions need to be applied[20].

• **Pharmacophore Modeling**: The AI can be used to automate pharmacophore creation and refinement.

• Integration with Cloud and Big Data: While big data infrastructures effectively manage enormous compound libraries, cloud computing makes it possible to conduct extensive virtual screening campaigns[21].

Benefits Comapred to traditional HTS -

• **Speed and Cost-Effectiveness:** In contrast to experimental HTS, which takes weeks or months to evaluate, millions of compounds can be assessed in silico in a matter of hours or days.
• **Expanded Chemical Space:** AI makes it possible to screen for hypothetical molecules that haven't been created yet .

• **Higher Hit Quality:** By reducing false positives and concentrating laboratory efforts on the most promising candidates, better prioritization improves hit quality.

3.3 Optimization of lead

Lead optimization, which involves modifying chemical structures to increase their potency, selectivity, safety, and developability, comes after screening has discovered promising "hits." Because there are so many potential chemical changes, this stage is crucial for turning an initial hit into a promising therapeutic candidate, but it is frequently time- and resource-intensive[22].

By directing chemists toward the most promising structural modifications and anticipating important features early in the pipeline, artificial intelligence (AI) is contributing to the modernization of lead optimization .

Property and AI's Role in Lead Optimization Proposed analogues' biological activity, binding affinity, solubility, permeability, metabolic stability, and toxicity are predicted by machine learning (ML) and deep learning (DL) models[12].

• **Multi-objective Optimization:** Instead of maximizing a single attribute, algorithms enable scientists find molecules with an ideal profile by balancing multiple parameters at once, such as potency , selectivity and ADMET[23] .

• **De novo Design & Generative Models:** Recurrent neural networks, generative adversarial networks (GANs), and variationalautoencoders generate novel chemical structures that are anticipated to meet predetermined standards (activity, safety, and synthetic feasibility).

• **Structure-based Modeling:** AI-powered docking and molecular dynamics forecast the impact of minor structural modifications on a molecule's ability to bind to its target[24].

• **Automated Synthesis Planning:** AI technologies reduce the design-make-test cycle by proposing synthetic pathways for molecules that are optimal.

Benefits Over conventional Approches -

• **Quicker Iteration:** Prior to synthesis, AI quickly assesses thousands of alterations in silico.

• Greater Success Rate: By anticipating undesired ADMET features early on, late-stage attrition is decreased .

• **Cost savings:** Reduces needless biological testing and synthesis of subpar candidates.

• **Exploration of Novel Chemical Space:** Structures beyond human intuition are suggested by generative models.

3.4 Drug Design from Scratch

Instead of altering already-existing drugs, de novo drug design involves creating completely new chemical entities with the necessary biological activity. The chemical space of potentially drug-like molecules is enormous ($>10^{60}$ structures), yet traditional methods rely on the intuition of medicinal chemists, fragment-

based design, or combinatorial chemistry. Since it cannot be explored experimentally, artificial intelligence (AI) is a perfect fit for this stage[25].

3.5 De novo Drug Design

• **Generative Models:** Generative Adversarial Networks (GANs) and VariationalAutoencoders (VAEs) learn patterns from known bioactive compounds to produce novel structures that are anticipated to satisfy physiochemical or activity criteria .

Real-time design improvement is possible through iteratively proposing novel molecules and receiving feedback on their anticipated "fitness" thanks to Reinforcement Learning (RL)[26].

• **Graph Neural Networks (GNNs):** These networks directly generate chemical graphs with advantageous characteristics by modeling atoms as nodes and bonds as edges[27].

• **Conditional generators:** These enable scientists to define desirable characteristics, such potency, lipophilicity, or lack of toxicity, and produce molecules that meet those requirements at
the same time.

• **Hybrid Approaches:** AI refines produced molecules for binding affinity and stability by combining it with docking, molecular dynamics, or quantum mechanics[28].

Benefits

• **Vast Chemical Space Exploration:** AI is capable of navigating beyond libraries that have been manufactured or purchased comercially .

• **Multi-objective optimization:** takes into account synthetic accessibility, potency, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) all at once.

• **Speed & Efficiency:** By recommending high-value candidates prior to synthesis, it reduces the design-make-test cycle.

• **Innovation:** Increases the likelihood of finding first-in-class medications by creating compounds with unique scaffolds or chemotypes.

3.6 Preclinical Development (ADMET Prediction & Toxicology)

Before a drug candidate goes through human trials, preclinical development assesses its pharmacokinetics, pharmacodynamics, and safety. In order to establish whether a molecule is suitable for further research, it is important to evaluate ADMET, which stands for Absorption, Distribution, Metabolism, Excretion, and Toxicity. In vitro tests, animal research, and rule-based models—such as Lipinski's "Rule of Five"—have historically been used in ADMET evaluation. Despite their necessity, these techniques can be costly, time-consuming, and may not always precisely forecast human consequences[29] .

This stage is being revolutionized by artificial intelligence (AI), which offers quick, data-driven predictions that direct study design and lower attrition.AI's Function in ADMET and Toxicity Forecasting

• **Predictive Modeling**: Deep learning (DL) networks and machine learning (ML) methods, such as random forests and support vector machines, forecast toxicity endpoints, such as hepatotoxicity and cardiotoxicity, as well as solubility, permeability, metabolic stability, and

Plasma protein Binding [30].

To predict the features of new compounds, AI models examine enormous datasets of chemical descriptors and experimental ADMET result .

• **Multi-Parameter Optimization**: AI may prioritize compounds with the best safety profiles by balancing competing requirements, such as potency vs. toxicity or solubility vs. permeability.

• **In Silico Toxicology:** Reactive metabolites, off-target interactions, or structural alarms connected to negative consequences are screened for by deep learning algorithms[31].

• **Metabolite Prediction:** AI detects potentially hazardous compounds and forecasts probable metabolic routes.

• **Integration with Omics Data:** Predicting the mechanisms driving toxicity is improved by combining transcriptomics, proteomics, and metabolomics data.

Benefits

• **Early Risk Identification:** Identifies ADMET liabilities before to expensive animal testing or synthesis.

• **Less Animal Use & Cost:** By concentrating on the most promising chemicals, less needless in

Vivo investigation are conducted .

• **Speed:** Preclinical timeframes are accelerated by evaluating hundreds of compounds in silico in

a matter of hours .

• **Increased Human Relevance**: Models that have been trained on data collected from humans, such as organ-on-chip or cell tests, may be better able to predict clinical outcomes.

3.7 Design and optimization of clinical trials -

In order to verify safety, efficacy, and proper dosage in human subjects, clinical trials are the last and most resource-intensive stage of drug development. Traditional trial designs can be costly, time-consuming, and prone to failure despite advancements in regulatory science; in fact, approximately half of Phase III trials fail because of issues with patient recruitment or poor efficacy. A useful technique for improving the effectiveness, predictability, and efficiency of clinical trials is artificial intelligence (AI)[11].

AI's role in clinical trial design includes protocol optimization, which finds the best study designs, outcomes, and sample sizes by analyzing patient registries, electronic health records (EHRs), and prevoius clinical trials data .

• **Patient Recruitment & Stratification:** Clustering algorithms divide patients into subgroups that are most likely to benefit from the treatment, while machine learning models search EHRs, genomes, and demographic data to find eligible participants .

• **Adaptive Trial Designs:** By enabling adaptive randomization, dose modification, or early ending based on interim results, reinforcement learning and Bayesian models help to minimize
Needless exposure and expense .

• **Synthetic Control Arms:** By leveraging past patient data, AI can create "virtual" comparison groups, which could eliminate the requirement for sizable placebo groups.

AI's Function in Trial Monitoring and optimization –

• **Forecasting Trial Results:** Algorithms assess the likelihood of success and feasibility by taking into account endpoints, patient availability, and past results of comparable drugs.

• **Real-Time Monitoring:** Throughout the experiment, AI technologies examine safety signals, unfavorable outcomes, and protocol deviations to enable prompt action.

• **Wearables & Remote Monitoring:** AI improves endpoint sensitivity and permits decentralized trials by processing continuous data streams (such as heart rate, glucose, and mobility) from wearable devices.

Benefits

• **Better Recruitment and Retention:** AI finds the correct patients more quickly, increasing
diversity and enrollment effectivness .

• **Lower Costs & Timelines:** Trial size and duration are decreased by virtual cohorts and optimized designs.

• **Greater Success Rates**: Adaptive approaches and better patient selection raise the possibility of proving effectivness .

• Patient-Centered Approach: Customized and adaptable study participation is supported by the integration of real-world data and remote monitoring.

4. Algorithms for Regression, Classification, and Clustering in Machine Learning and Deep Learning

4.1 Regression

• **Definition**: A method of supervised learning that uses input variables to predict a continuous numerical value .

•Uses in pharamacueticals research and development -

1]Forecasting drug candidates' biological activity (IC_{50}, Ki, EC_{50}).

Pharmacokinetic characteristics such half-life, volume of distribution, and clearance are estimated.

2]Predicting pateint outcomes or dosage –response curves -

3]Random forest regression, gradient boosting, lasso/ridge regression, and linear regression are a few examples of algorithms.

Classification

• **Definition**: An algorithm classifies an item into one of several distinct categories in a supervised learning activity .

• uses –

- Determining if a chemical is "hit" or "non-hit" in relation to a target.
- Differentiating between harmful and non-toxic compounds.
- In clinical datasets, distinguishing responders from non-responders.
- Some examples of algorithms are naïve Bayes, deep neural networks, support vector machines (SVM), decision trees, and logistic regression.

Clustering

• **Definition:** Clustering is an unsupervised learning method that uses similarity rather than labels to group data points into cluster .

•Uses -

-Chemical structures with comparable scaffolds or features are grouped together.

- Dividing patient groups according to therapy response, illness progression, or genetic profile.
- Grouping the results of high-throughput screening into relevant clusters for additional examination.

• Gaussian mixture models, DBSCAN, hierarchical clustering, and k-means are a few examples of methods.

4.2Convolutional and Recurrent Models in Neural Networks

Artificial Neural Networks (ANNs) are computational models made up of interconnected nodes, or "neurons," stacked in layers and inspired by the composition and operations of the human brain[33].

• **Function:** Using weighted connections and iterative training, discover intricate, frequently non-linear relationships between input and output variables.

•Pharmaceutical research application –

-Estimating the binding affinity of a medication to its target.

-Simulating the properties of absorption, distribution, metabolism, excretion, and toxicity (ADMET).

o Using omics data analysis to find biomarkers

Convolutional Neural Networks (CNNs) are a specific kind of neural network that uses "convolution" procedures to automatically extract structural or spatial patterns from data.
• Outstanding ability to identify hierarchical patterns and localized features is a key quality[24].

• Uses in medicine and drug development:

o Examining histology or medical pictures (e.g., tumor detection)

o Protein-ligand binding prediction based on three-dimensional molecular structures.

o Chemical library screening using grids or pictures.

Neural Network that recur [RNNs]

• **Definition:** Neural networks that retain an internal "memory" of prior inputs are intended to process sequential or time –dependent data .

• **Variants:** Long Short-Term Memory (LSTM) and Gated Recurrent Unit (GRU) networks are appropriate for lengthy sequences since they get around issues like vanishing gradients[36].

• Pharmaceutical science applications include:

o Natural language processing (e.g., mining electronic health data or biomedical literature).

o Simulating time trends in patient monitoring or clinical data.

o Creating new molecules as SMILES strings, which are sequences based on text or graph.

4.3 Reinforcement Learning to Generate molecules to

In the machine-learning paradigm known as reinforcement learning (RL), an agent gains decision-making skills by interacting with its surroundings and getting rewarded or punished for its behaviors[37].

The creation of a molecule is treated as a sequential choice problem when RL is used in drug development; atoms or fragments are added gradually, and the model is trained to maximize a score associated with the intended pharmacological qualities[38].

The Function of RL in Molecule Desgin -

• **State:** The partially constructed molecule, such as a molecular graph or SMILES string.

•**Action:** Adding, taking away, or changing bonds or atoms.

• **Reward Function:** A numerical rating that indicates how effectively the chemical satisfies predetermined goals like

A target protein's binding affinity

-Lipophilicity or Solubility

o ADMET profile prediction

o novelty or synthetic accessiblity

• Agent/Policy: A neural network that determines which activities result in the greatest total reward.

• Environment: The area of chemistry that was investigated throughout training[39].

Benefits

The ability of RL to balance conflicting objectives (such as potency, selectivity, toxicity, and synthetic feasibility) within a single framework is known as multi-objective optimization.

• **Novel Chemical Space Exploration:** Promotes creativity by rewarding diversity and novelty while adhering to limitation .

• Effectiveness: Produces excellent choices without listing every potential chemical in detail.

Uses

•The creation of de novo molecules for challenging or "undruggable" targets.

•Improving the potency or ADMET characteristics of current scaffolds.

•Using docking or molecular-dynamics simulations in conjunction to highlight promising molecules and improve score .

•Combining generative models (such as graph neural networks and variationalautoencoders) with hybrid RL systems[40]

5. Integration with other Technologies

5.1 High – Throughout Screening [HTS] combined with AI

A key component of early drug development is high-throughput screening (HTS), which enables scientists to quickly test hundreds of thousands of molecules against biological targets.

Even though HTS produces vast amounts of activity data, it is frequently sluggish, expensive, and prone to false positives and negatives to analyze and prioritize hits.

In order to increase speed, accuracy, and efficiency, HTS is progressively integrating artificial intelligence (AI)[41].

AI's role in HTS

• Data Cleaning & Curation: AI systems automatically adjust for systematic mistakes (such plate effects), Standardize assay data and identify outliners .

• Predictive Modeling: o Prior to conducting assays, virtual screening, or machine learning (ML) and deep learning (DL) models trained on past HTS data can identify which compounds are most likely to be active .

o By prioritizing library subsets, Quantitative Structure–Activity Relationship (QSAR) models lessen the experimental load .

• **Active Learning:** AI optimizes the ratio of exploration to exploitation by iteratively choosing the most instructive compounds for testing .

• Image-based Screening: o Convolutional neural networks (CNNs) use microscope pictures to detect phenotypic changes in cell-based HTS, allowing for high-content screening of intricate biological impacts[42].

Benefits

•**Greater Hit Rates:** Libraries are enriched for likely actives using AI-guided prioritizing.

•**Time and Money Savings:** Fewer substances require physical testing.

•**Scalable Insight**: Discovers hidden correlations between structure and activity from millions of observations.

•**Phenotypic Discovery:** AI is able to pick up on minute morphological cues that human scrutiny might miss.

Uses

Prior to wet-lab screening, ultra-large virtual libraries are pre-filtered. Assay parameters and experimental design are optimized

•Using cheminformatics and multi-omics data to create smarter screens.

• Finding new bioactivities in libraries that have been repurposed[43].

5.2Omics data (genomics, proteomics, and metabolomics) combined with AI -

Large volumes of biological data are produced by omics technologies, including transcriptomics, proteomics, metabolomics, and genomes. These technologies offer insights into medication targets, disease causes, and patient responses. However, traditional analysis techniques face difficulties because to the high dimensionality, variability, and volume of omics datasets. Machine learning (ML) and deep learning (DL), two subfields of artificial intelligence (AI), provide strong instruments for identifying significant patterns and expediting pharmaceutical research[12].

AI's function in genomics

• **Variant Prioritization:** AI systems rank potential genes for therapeutic targeting based on the identification of mutation linked to disease .

• **Gene Expression Analysis:** ML/DL techniques use RNA-seq or microarray data to identify biomarkers and regulatory networks.

• Precision Medicine: AI uses genomic profiles to forecast adverse reactions or therapeutic responses for individual patients.

AI's function in proteomics

•**Predicting Protein Function:** AI makes predictions about interaction networks, post-translational changes, and protein architectures.

•**Target Discovery:** Important proteins implicated in disease pathways are found using network-Based techniques .

• **Drug-Protein Interaction:** Potential off-target effects and binding affinities are predicted by deep learning.

AI's Function in Metabolomics

• **Biomarker Discovery**: AI finds metabolic markers linked to illness conditions or medication effectiveness.

• **Pathway Analysis:** To comprehend toxicity or mechanism-of-action, machine learning reconstructs metabolic pathways .

• **Therapeutic Monitoring:** AI evaluates metabolite profiles for patient stratification and pharmacokinetic research.

Benefits

• **Omics Layer Integration:** AI can integrate proteomic, metabolomic, and genomic data to provide a systems-level knowledge of illness and therapy.

• **Pattern Recognition:** This technique finds subtle, non-linear relationships that traditional statistics would Overlook .

• Predictive Power: Enhances patient categorization, adverse effect prediction, and the identification of new pharmacological targets.

Obstacles and Things to Think About

• Data Standardization & Quality: Omics datasets are frequently heterogeneous, noisy, and platform-specific.

• High Dimensionality: Improper management of a large number of variables may result in overfitting.

• Interpretability: Mechanistic understanding may be complicated by complex models that are "black boxes."

• Computational Requirements: Significant computer resources are needed to process and integrate multi-omics datasets.

5.3 The function of big data and cloud computing –

The ability to store, handle, and analyze large datasets is crucial for the integration of artificial intelligence (AI) into drug development and discovery. Big data and cloud computing together have become indispensable for contemporary pharmaceutical research because they allow for scalable, effective, and cooperative workflows.

Big Data in the Search for New Drugs

• Definition: Describes incredibly huge and intricate datasets that are challenging to handle using conventional computing methods.

• Pharmaceutical R&D sources:

Results of high-throughput screening (HTS)

o Electronic health records and clinical trials o Omics data (genomics, proteomics, metabolomics)

o Chemical databases, patents, and scientific publications

Function of Cloud Computing

• Scalable Processing & Storage: Cloud systems offer high-performance computing power to manage big datasets as well as nearly infinite storage.

• Economical: Minimizes the requirement for internal servers, infrastructure, and upkeep[44].

• Collaboration & Accessibility: Real-time data access, sharing, and analysis are available to researchers anywhere.

• Integration with AI Tools: Cloud-based frameworks make it easier to train deep learning and big machine learning models for clinical trial optimization, ADMET prediction, virtual screening, and molecule synthesis[45].

6.Success Stories and Case Studies

AI-Developed Medicines in Clinical Experiments

Artificial Intelligence (AI) has advanced beyond early drug discovery to include the design of drugs that have made it into clinical trials. AI speeds up the process of turning computational forecasts into promising medication candidates, which could shorten time to market and increase success rates[46].

6.1 AI's role in drug design that is ready for clinical trials

• Molecular Generation & Optimization: AI creates compounds with anticipated safety, efficacy, and viability for synthesis.

• Target Prioritization: Assists in choosing applicants who have the best chance of surviving human trials.

• ADMET Prediction: Lowers the possibility of toxicity or subpar pharmacokinetics leading to late-stage failures.

• Patient stratification: AI improves trial design and endpoint sensitivity by identifying subpopulations that are more likely to respond[47].

Benefits

• Accelerated Development: Compared to conventional drug discovery timelines, AI-designed compounds can enter clinical testing considerably more quickly.

• Greater Chance of Success: Phase I/II trial failure risk is decreased by early in silico optimization.

• New Mechanisms of Action: AI is able to produce first-of-a-kind molecules that traditional techniques could miss.

6.2 Startups and Industry Partnerships in AI-Powered Drug Discovery –

A new age of corporate partnerships and start-ups has been sparked by the incorporation of Artificial Intelligence (AI) into pharmaceutical research, which has helped to close the gap between computational innovation and real-world medication development. These collaborations use domain knowledge, big datasets, and AI skills to speed up drug discovery, improve clinical trials, and cut expenses[48].

Important Industry Partnerships

• Exscientia& Sumitomo Dainippon Pharma: o AI-driven design of OCD treatment DSP-1181, cutting discovery times to less than a year.

• BenevolentAI& AstraZeneca: o Joint initiatives in inflammatory and oncological disorders, employing AI to analyze biomedical data and find new targets.

• Pfizer with Insilico Medicine: o Collaboration centered on preclinical optimization and AI-powered chemical creation for fibrosis and aging-related disorders

New Startups

• Insilico Medicine (USA/Hong Kong): Focuses on de novo drug design using predictive biology and generative chemistry.

• Recursion Pharmaceuticals (USA): Identifies potential treatments for uncommon diseases by analyzing cellular imaging using artificial intelligence.

• Atomwise (USA): Effectively finds small-molecule drug candidates through virtual screening based on deep learning.

• Exscientia (UK): Uses AI and medicinal chemistry to optimize leads and hit-to-lead processes quickly.

Benefits of Partnerships and Startups

• Enhanced R&D: AI makes it possible to identify targets, find hits, and optimize leads more quickly.

• Cost Savings: Predictive computations cut down on needless synthesis and testing.

• Innovation: New methods such as multi-omics integration, reinforcement learning, and generative models are investigated by startups.

• Cross-disciplinary expertise: builds stronger drug discovery pipelines by combining clinical, computational, and pharmacological knowledge.

7. Difficulties and Restrictions

7.1 Availability and Quality of Data

The quality and availability of data are critical to the effectiveness of artificial intelligence (AI) in drug research and discovery. Large, precise, and well-annotated datasets are necessary for AI algorithms—especially machine learning and deep learning—to identify significant patterns and generate trustworthy predictions[48].

The Value of High-Quality Data

• Accuracy and Consistency: Inaccurate forecasts may result from mistakes, missing values, or discrepancies in experimental or clinical data.

• Representativeness and Diversity: Models developed on small datasets might not be able to generalize to novel chemical scaffolds, patient groups, or disease scenarios.

• Annotation and Standardization: Reproducibility and interpretability are enhanced by well-labeled datasets with defined formats (such as SMILES for molecules and structured omics data).

• Avoiding Bias: Unbalanced or skewed datasets may cause AI forecasts to prioritize certain drugs or patient groups unjustly.

Difficulties with Data Availability

• Fragmented Sources: Relevant information may be found in a variety of formats in databases, patents, clinical trials, literature, and internal pharmaceutical repositories.

• Restricted Access: Training AI models may be hampered by proprietary or private datasets.

• Diverse Data Types: It takes a lot of computing power to integrate chemical, biological, genomic, and clinical datasets.

• Sparse Data for Rare Diseases: The amount of useful data for AI training is constrained by small patient groups or unusual targets.

Strategies to Improve Data Quality and Availability

• Data Curation: Manual and automated cleaning of datasets to correct errors and standardize formats.

• Data Augmentation: Techniques such as SMILES enumeration, synthetic data generation, or transfer learning to enhance limited datasets.

• Collaborative Data Sharing: Partnerships between academia, industry, and public databases (e.g., PubChem, ChEMBL, PDB) increase the diversity and size of available datasets.

• Use of High-Quality Public Omics Databases: Integrating genomics, proteomics, and metabolomics datasets enhances model performance and predictive accuracy

7.2 AI Model Interpretability

The degree to which a person can comprehend the choices or forecasts made by an Artificial Intelligence (AI) model is known as interpretability, or explainability. Interpretability is essential for scientific knowledge, regulatory compliance, and confidence in pharmaceutical research and treatment[49].

Relevance to Drug Development

• Regulatory Compliance: Decisions that impact clinical trial results or patient safety must have a clear rationale, according to regulatory bodies like the FDA and EMA.

• Scientific Understanding: By using transparent models, scientists can comprehend the reasons behind a compound's projected levels of activity, toxicity, or ineffectiveness.

• Trust and Adoption: If stakeholders, including physicians and medicinal chemists, are able to understand the logic behind AI forecasts, they are more inclined to accept them.

• Error Diagnosis: Interpretable models assist in locating biases, errors, or algorithmic or dataset restrictions[50].

• Heterogeneous Data: Interpretability becomes more difficult when multi-omics, chemical, and clinical datasets are integrated.

• Standardization: There aren't any widely recognized frameworks for elucidating AI choices in pharmaceutical settings.

Methods for Enhancing Interpretability

• Model-Agnostic Methods: LIME, SHAP (Shapley Additive Explanations), and feature importance rankings are some of the tools that aid in the explanation of complex model predictions[51].

• Attention Mechanisms: In deep learning, attention layers draw attention to the aspects of input data that have the greatest impact on predictions.

• Visualization Techniques: To help with interpretation, graphs, heatmaps, or network diagrams show the correlations the model has learned[51].

7.3 Regulatory and Ethical Aspects of AI-Powered Drug Development

There are new ethical and regulatory issues when artificial intelligence (AI) is included into pharmaceutical research and development. Maintaining scientific integrity, promoting the adoption of AI technology, and safeguarding patient safety all depend on ethical behavior and compliance[52].

Regulatory Aspects

• Validation and Reproducibility: AI models used in clinical trials or drug research must be transparent, reproducible, and approved by regulatory bodies like the FDA and EMA.

• Data Compliance: AI systems need to abide by local laws pertaining to medical and clinical data as well as data protection and privacy legislation like HIPAA and GDPR[53].

• Risk Assessment: Models' prediction accuracy, bias, and possible influence on clinical outcomes must all be carefully examined.

• Documentation: Regulatory reviews frequently need for thorough documentation of the model architecture, training datasets, and decision-making procedures.

• Integration with Conventional Evidence: In order to meet regulatory standards, AI forecasts should supplement rather than replace traditional preclinical or clinical evidence[54].

Techniques for Ethical and Compliant Use

• Put in place strong data governance mechanisms for gathering, analyzing, and disseminating data.

• Use explainable AI (XAI) techniques to improve credibility and openness.

• Perform bias audits and keep an eye on model results to ensure fairness.

• To ensure that AI workflows adhere to compliance norms, consult with regulatory agencies early in the development process.

Encourage multidisciplinary cooperation between regulatory specialists, ethicists, doctors, and computational scientists[55].

8.Prospects for the Future

8.1 Explainable AI for Approval by Regulators

The term "explainable AI" (XAI) describes methods and strategies that help people comprehend, analyze, and make sense of the predictions and choices made by artificial intelligence algorithms. XAI is essential for obtaining regulatory approval in drug discovery and development, guaranteeing that AI-driven choices are reliable, repeatable, and scientifically sound[56].

Relevance in a Regulatory Setting

• Transparency: Decisions impacting clinical trial results, medication efficacy, and patient safety must be transparently justified to regulatory bodies.

• Adoption & Trust: Regulators, physicians, and pharmaceutical stakeholders can have faith in AI-generated forecasts thanks to explainable models[57].

• Error Detection: XAI assists in locating biases, discrepancies, or mistakes in the input data or model[58].

• Integration with Traditional Evidence: Facilitates decision-making in accordance with regulatory standards by bridging the gap between AI forecasts and preclinical or clinical data that has been established.

Methods for Explainable AI

Model-Agnostic Approaches:

o Shapely Additive Explanations, or SHAP, measures how much each attribute contributes to the model's[59] prediction.

o LIME (Local Interpretable Model-agnostic Explanations): This method uses an interpretable model to locally approximate the complex model in order to explain individual predictions[60].

• Attention Mechanisms: Emphasize which input components—such as omics characteristics or molecular substructures—had the biggest impact on the prediction.

• Feature Importance Ranking: Offers a global perspective on which inputs or descriptors have the most influence on model results.

• Visualization Tools: Heatmaps, network diagrams, and graphs that show the links between inputs and expected results that have been learned[61].

Uses of AI in Pharmaceuticals

Drug Target Selection: Describes the rationale for the prioritization of a certain protein or pathway for action.

• Hit-to-Lead Optimization: Provides support for molecular changes recommended by generative models[62].

• ADMET and Toxicity Prediction: Identifies molecular or structural characteristics that influence anticipated toxicity.

• Clinical Trial Optimization: Describes endpoint forecasts or patient stratification for regulatory evaluation[63].

Benefits

• Promotes compliance and regulatory confidence.

• Promotes scientific examination and peer evaluation of AI-driven discoveries.

• By permitting human specialists to evaluate and validate model judgments, it lowers the possibility of unanticipated failures[64].

8.2 AI in Personalized and Accurate Medicine

By taking into account individual differences in genetics, environment, and lifestyle, precision medicine seeks to provide the appropriate medication to the right patient at the right time[65]. Through the analysis of intricate datasets and the production of useful insights for patient-specific treatment plans, artificial intelligence (AI) plays a critical role in enabling personalized treatments[66].

AI's Place in Precision Healthcare

• Patient stratification: To divide patients into subgroups that are most likely to benefit from a given treatment, machine learning algorithms examine genetic, proteomic, metabolomic, and clinical[67] data.

• Predicting Drug Response: AI makes predictions about which patients may benefit from a medication or have negative side effects, allowing for safer and more efficient medical care.

• Biomarker Discovery: AI finds metabolic, proteomic, or genomic biomarkers that might inform treatment choices and track the course of diseases[68].

- **Treatment Optimization:** Reinforcement learning and optimization algorithms suggest personalized dosing regimens and combination therapies based on patient-specific data[69].

Applications in Drug Discovery and Development

- **Oncology:** AI models predict tumor response to targeted therapies based on genomic alterations[70].
- **Rare and Complex Diseases:** AI helps identify personalized interventions where patient populations are small and heterogeneous[71].
- **Pharmacogenomics:** AI integrates genomic data to predict metabolism, efficacy, and toxicity, improving drug safety and efficacy[72].
- **Adaptive Clinical Trials:** AI-guided trial designs select patients most likely to respond, reducing sample size and trial duration[74].

- Benefits

  • Enhanced Effectiveness: Customizes treatments for each patient, optimizing therapeutic outcomes[73].

  • Decreased Adverse Effects: identifies and steers clear of therapies that could be hazardous for particular patients[74].

  • Accelerated Drug Development: By focusing on subpopulations with a high potential of responding, this

approach enables targeted clinical trials[89].

• Data-Driven Decisions: Combines real-world data and multi-omics to provide accurate treatment plans[75].

8.3AI's role in robotics and automation

• Automated Synthesis: AI directs robotic systems to organize and carry out the chemical synthesis of new molecules with the least amount of human involvement[76].

.

• High-Throughput Screening (HTS): AI ranks compounds and deciphers intricate readouts, while robotic systems run thousands of experiments concurrently[97].

o Phenotypic screening accuracy is increased through integration with AI-based image analysis[78].

• Self-Driving Labs: AI systems create trials on their own, adjust reaction parameters, and develop molecules iteratively[84].

o Feedback loops between robotic experiments and AI forecasts speed up decision-making and cut down on iterations of trial and error[79].

• Automated Data Collection and Analysis: o AI and robotics work together to guarantee consistent, high-quality data collection, which powers predictive models for further design iterations[80].

Benefits

• Speed: By carrying out and evaluating trials more quickly than manual procedures, it significantly reduces the time needed for drug discovery[81].

• Precision and Reproducibility: Lowers variability in experimental processes and human error[85].

• Effective Chemical Space Exploration: With AI direction, robots can create and test thousands of molecules, improving the ability to uncover interesting leads[82].

• Cost-Effectiveness: Lowers the expenses of materials and labor related to manual experimentation[83]

Obstacles and Things to Think About -

• High Initial Investment: It takes a substantial amount of money and technological know-how to set up robotic labs with integrated AI[86].

• Complex Integration: It might be technically difficult to integrate hardware, software, and AI algorithms into a smooth workflow[97].

• Data Management: Robust processing and storage systems are necessary to handle the massive amounts of experimental data produced by robotic platforms[98].

• Human Oversight: Expert supervision is required to maintain scientific validity and handle unexpected outcomes, even while automation decreases regular work[100].

conclusion-

From target identification to clinical trials, artificial intelligence (AI) is completely changing the drug discovery and development process. AI makes it possible to quickly and affordably explore chemical and biological space, anticipate ADMET properties, build de novo molecules, and develop patient-specific treatment plans by combining machine learning, deep learning, reinforcement learning, and generative models.

By eliminating the need for conventional trial-and-error methods, facilitating high-throughput screening, integrating multi-omics data, and assisting with predictive and adaptive clinical trials, artificial intelligence (AI) improves accuracy, efficiency, and creativity. AI in conjunction with automation, robots, cloud computing, and big data speeds up the research process and makes collaborative, scalable, and repeatable workflows possible.

The use of AI in pharmaceutical R&D necessitates close attention to data quality, interpretability, ethical considerations, and regulatory compliance despite its revolutionary promise. To win over stakeholders, regulators, and clinicians, explainable AI and strong validation techniques are essential. Additionally, cross-disciplinary alliances, start-ups, and industrial collaborations are propelling AI's practical applications and proving that it is feasible to produce pharmaceuticals that are suitable for clinical trials.
To sum up, artificial intelligence (AI) is revolutionizing medication discovery by providing previously unheard-of chances for creativity, effectiveness, and customized treatments. The future of pharmaceutical science will be shaped by ongoing developments in algorithms, data integration, and ethical frameworks that will hasten the creation of safe, efficient, and patient-centered treatments.

Reference-

1. Bennani YL. Drug discovery in the next decade: innovation needed ASAP. Drug Discovery Today. 2011 Sep 1;16(17-18):779-92. https://doi.org/10.1016/j.drudis.2011.06.004
2. Nicolaou KC. Advancing the drug discovery and development process. Angewandte Chemie. 2014 Aug 25;126(35):9280-92.**https://doi.org/10.1002/ange.201404761**
3. Taye MM. Understanding of machine learning with deep learning: architectures, workflow, applications and future directions. Computers. 2023 Apr 25;12(5):91.**https://doi.org/10.3390/computers12050091**

4. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1916.**https://doi.org/10.3390/pharmaceutics15071916**
5. Mirakhori F, Niazi SK. Harnessing the AI/ML in drug and biological products discovery and development: the regulatory perspective. Pharmaceuticals. 2025 Jan 3;18(1):47.**https://doi.org/10.3390/ph18010047**
6. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017 Nov 1;3(4):651-7. https://doi.org/10.1016/j.trci.2017.10.005
7. Verma S, Pathak RK. Discovery and optimization of lead molecules in drug designing. InBioinformatics 2022 Jan 1 (pp. 253-267). Academic Press. https://doi.org/10.1016/B978-0-323-89775-4.00004-3
8. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Current drug metabolism. 2006 Feb 1;7(2):165-82. https://doi.org/10.2174/138920006775541552
9. Cook N, Hansen AR, Siu LL, Razak AR. Early phase clinical trials to identify optimal dosing and safety. Molecular Oncology. 2015 May 1;9(5):997-1007. https://doi.org/10.1016/j.molonc.2014.07.025
10. Mazanetz M, Law R, Whittaker M. Hit and Lead Identification from fragments. De novo molecular design. 2013 Nov 13:143-200. **https://doi.org/10.1002/9783527677016.ch6**
11. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug discovery today. 2012 Oct 1;17(19-20):1088-102. https://doi.org/10.1016/j.drudis.2012.05.007
12. Pomerol JC. Artificial intelligence and human decision making. European Journal of Operational Research. 1997 May 16;99(1):3-25.https://doi.org/10.1016/S0377-2217(96)00378-5
13. Faiyazuddin M, Rahman SJ, Anand G, Siddiqui RK, Mehta R, Khatib MN, Gaidhane S, Zahiruddin QS, Hussain A, Sah R. The impact of artificial intelligence on healthcare: a comprehensive review of advancements in diagnostics, treatment, and operational efficiency. Health Science Reports. 2025 Jan;8(1):e70312. **https://doi.org/10.1002/hsr2.70312**
14. Zhang J, Williams SO, Wang H. Intelligent computing system based on pattern recognition and data mining algorithms. Sustainable Computing: Informatics and Systems. 2018 Dec 1;20:192-202.https://doi.org/10.1016/j.suscom.2017.10.010
15. Mishra C, Gupta DL. Deep machine learning and neural networks: An overview. IAES international journal of artificial intelligence. 2017 Jun 1;6(2):66. 10.11591/ijai.v6.i2.pp66-73
16. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18(6):463-77. doi:10.1038/s41573-019-0024-5
17. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–1250. doi:10.1016/j.drudis.2018.01.039.
18. Dara S, Dhamercherla S, Jadav SS, Madhu Babu CH, Jawed Ahsan M, et al. Machine learning in drug discovery: a review. Artif Intell Rev. 2022;55:1947–1999. doi:10.1007/s10462-021-10058-4.

19. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77. doi:10.1038/s41573-019-0024-5.
20. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–1250. doi:10.1016/j.drudis.2018.01.039.
21. Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov. 2021;16(9):949–59. doi:10.1080/17460441.2021.1909567.
22. Kim H, Kim E, Lee I, Bae B, Park M, Nam H. Artificial intelligence in drug discovery: a comprehensive review of data-driven and machine learning approaches. Biotechnol Bioprocess Eng. 2020;25(6):895–930. doi:10.1007/s12257-020-0049-y.
23. Dara S, Dhamercherla S, Jadav SS, Madhu Babu CH, Jawed Ahsan M, et al. Machine learning in drug discovery: a review. Artif Intell Rev. 2022;55:1947–1999. doi:10.1007/s10462-021-10058-4.
24. Kim J, Lee D, Park K, et al. Comprehensive survey of recent drug discovery using deep learning. Int J Mol Sci. 2021;22(18):9983. doi:10.3390/ijms22189983.
25. Hassanien A-E, et al. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev. 2023; (systematic review). doi:10.1007/s10462-022-10306-1.
26. Blanco-González A, Cabezón A, Seco-González A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceutics. 2023;16(6):891. doi:10.3390/ph16060891.
27. Hasselgren C, et al. Artificial Intelligence for Drug Discovery: Are We There Yet? Annu Rev Pharmacol Toxicol. 2024;64:527–550. doi:10.1146/annurev-pharmtox-040323-040828.
28. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discov Today. 2021;26(2):511–524. doi:10.1016/j.drudis.2020.12.009.
29. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: A discussion of chemical and biological data used for AI in drug discovery. Drug Discov Today. 2021;26(4):1040–1052. doi:10.1016/j.drudis.2020.11.037.
30. umper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi:10.1038/s41586-021-03819-2.
31. Polykovskiy D, Zhebrak A, Vetrov D, et al. Entangled conditional adversarial autoencoder for de novo drug discovery. Mol Pharm. 2018;15(10):4398–4405. doi:10.1021/acs.molpharmaceut.8b00742.
32. Jiménez J, Skalic M, Martinez-Rosell G, De Fabritiis G. LigVoxel: Inpainting binding pockets using 3D-CNNs. Bioinformatics. 2019;35(2):243–250. doi:10.1093/bioinformatics/bty486.
33. Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37:1038–1040. doi:10.1038/s41587-019-0224-x.

34. Yang KK, Wu Z, Bedbrook CN, Arnold FH. Learned protein representations for engineering. Curr Opin Struct Biol. 2018;50:49–57. doi:10.1016/j.sbi.2018.01.001.
35. Gawehn E, Hiss JA, Schneider G. Deep learning in drug discovery. Mol Inform. 2016;35(1):3–14. doi:10.1002/minf.201500004.
36. Crossley S, Prasad R, et al. Applications of generative models for molecule design: a survey. Chem Rev. 2021;121(1):1–36. doi:10.1021/acs.chemrev.0c00941.
37. Rifaioglu AS, Atalay V, Martin MJ, Cetin-Atalay R, Atalay V, Doğan T. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and datasets. Brief Bioinform. 2020;21(5):1878–1903. doi:10.1093/bib/bbz158.
38. Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C. MoleculeNet: a benchmark for molecular machine learning. Chem Sci. 2018;9:513–530. doi:10.1039/c7sc02664a.
39. Lenselink EB, ten Dijke N, Bongers B, Papadatos G, van Vugt-Lussenburg BM, IJzerman AP, van Westen GJP. Beyond the hype: deep learning for medicinal chemistry. J Chem Inf Model. 2017;57(8):1972–1987. doi:10.1021/acs.jcim.7b00101.
40. Thafar M, Bin Raies A, Albaradei S, Essack M, Bajic VB. Comparison study of computational prediction tools for drug–target binding affinities. Front Chem. 2019;7:1–19. doi:10.3389/fchem.2019.00807.
41. Reker D. Practical considerations for active machine learning in drug discovery. Drug Discov Today Technol. 2019;32–33:73–79. doi:10.1016/j.ddtec.2020.06.001.
42. Yang H, Luo H, Han Z. Integration of multi-omics data and machine learning in drug discovery. Trends Pharmacol Sci. 2020;41(1):54–66. doi:10.1016/j.tips.2019.11.003.
43. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286. doi:10.1093/biostatistics/kxx069.
44. Schwartz DM, Lindor NM, et al. Model-informed drug development: role of AI and machine learning in R&D decisions. Clin Pharmacol Ther. 2020;108(2):221–231. doi:10.1002/cpt.1770.
45. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13. doi:10.1016/j.cell.2020.01.021.
46. . Nat Mach Intell. 2020;2:573–584. doi:10.1038/s42256-020-00207-4.
47. Lavecchia A. Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discov Today. 2019;24(3):733–740. doi:10.1016/j.drudis.2018.12.006.
48. Serrano-Antón D, et al. Artificial intelligence applications in drug discovery: an up-to-date review. Pharmaceutics. 2024;16(4):XXX. doi:10.3390/ph1604XXXX.
49. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. *Discover Pharmaceutical Sciences*. 2025;1:7. doi:10.1007/s44395-025-00007-3. SpringerLink

50. Guo S, Zhang D, Wang H, An Q, Yu G, Han J, Jiang C, Huang J. Computational and systematic analysis of multi-omics data for drug discovery and development. *Frontiers in Medicine*. 2023;10:1146896. doi:10.3389/fmed.2023.1146896. Frontiers
51. Wang A, Xiu X, Liu S, Qian Q, Wu S. Characteristics of Artificial Intelligence Clinical Trials in the Field of Healthcare: A Cross-Sectional Study on ClinicalTrials.gov. *Int J Environ Res Public Health*. 2022;19(20):13691. doi:10.3390/ijerph192013691. MDPI
52. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. *Drugs and Drug Candidates*. 2024;3(1):148-171. doi:10.3390/ddc3010009. MDPI
53. Mridula Chauhan, Shivansh Kumar, Arpon Biswas, Mukesh Kumar, Sarvesh Kumar Verma, Anjali Mishra, Vaishali Singh, Amol Chhatrapati Bisen, Sristi Agrawal, Abhijit Deb Choudhury, Ramakrishna Rayiti, Rabi Sankar Bhatta. A Comprehensive Review of the Advancement in Omic Technologies in the Field of Drug Discovery and Development. *Letters in Drug Design & Discovery*. 2024;21(16):3319-3331. doi:10.2174/0115701808287654240126112003. Bentham Science
54. Wang J, Pun FW, Polykovskiy D, Sun C, Levitt M, Aspuru-Guzik A, Zhavoronkov A. PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery. *Journal of Chemical Information and Modeling*. 2023;14(6):1443-1452. doi:10.1021/acs.jcim.3c01619. American Chemical Society Publications
55. Avinash Kumar, Suvarna G. Kini, Ekta Rathi. A Recent Appraisal of Artificial Intelligence and In Silico ADMET Prediction in the Early Stages of Drug Discovery. *Mini-Reviews in Medicinal Chemistry*. 2021;18:2788-2800. doi:10.2174/1389557521666210401091147. OUCI
56. A.J. Kazi, M.A. Gurav, S.R. Patil, P.V. Ritthe, V.M.D. Dharashive, S.D. Shafi, D.S. (et al.) The Impact of Artificial Intelligence on Drug Discovery; A Comprehensive Review. *Asian Journal of Pharmaceutical Research and Development*. 2024;(Vol.12 No.2):171-178. doi:10.22270/ajprd.v11i3.1230. Ajprd
57. Rahul Swamy Tirunagari. Role of Artificial Intelligence (AI) Tools and Machine Learning (ML) in Clinical Trials for FDA Approval of Pharmaceutical Drugs: A Comprehensive Review. *Int J Pharm Anal Res.* 2024;13(3):392-398. doi:10.61096/ijpar.v13.iss3.2024.392-398. IJPAR
58. Özçelik R, van Tilborg D, Jiménez-Luna J, Grisoni F. Structure-Based Drug Discovery with Deep Learning. *ChemBioChem*. 2023;24(13):e202200776. doi:10.1002/cbic.202200776 chemistry-europe.onlinelibrary.wiley.com
59. Askr H, Elgeldawi E, Aboul Ella Hassanien H, Elshaier YM, Gomaa MM. Deep learning in drug discovery: an integrative review and future challenges. *Artificial Intelligence Review*. 2022;56:5975-6037. doi:10.1007/s10462-022-10306-1 SpringerLink+2PubMed+2
60. Koutroumpa NM, Papavasileiou KD, Papadiamantis AG, Melagraki G, Afantitis A. A Systematic Review of Deep Learning Methodologies Used in the Drug Discovery Process with Emphasis on In Vivo Validation. *Int J Mol Sci*. 2023;24(7):6573. doi:10.3390/ijms2406573 PMC+1

61. Li H, Zou L, Alzobair H, Kowah J, He D, Liu Z, et al. A compact review of progress and prospects of deep learning in drug discovery. *J Mol Model*. 2023;29(4):54. doi:10.1007/s00894-023-05492-w Space Frontiers
62. A Review of Deep Learning-Based Approaches for Detection and Diagnosis of Diverse Classes of Drugs. *Archives of Computational Methods in Engineering*. 2023;30:3867-3889. doi:10.1007/s11831-023-09936-7 SpringerLink
63. Šícho M, Luukkonen S, van Westen GJP, et al. DrugEx: Deep Learning Models and Tools for Exploration of Drug-Like Chemical Space. *J Chem Inf Model*. 2023;63(12):3629-3636. doi:10.1021/acs.jcim.3c00434 American Chemical Society Publications
64. Zheng P, Zeng X, Wang X, Ding P. Editorial: Artificial intelligence and machine learning for drug discovery, design and repurposing: methods and applications. *Front Pharmacol*. 2023;14:1333747. doi:10.3389/fphar.2023.1333747 Frontiers
65. "Deep learning and artificial intelligence for drug discovery, application, challenge, and future perspectives." *Discover Applied Sciences*. 2025;7:533. doi:10.1007/s42452-025-06991-6 SpringerLink
66. Teodoro D, Naderi N, Yazdani A, Zhang B, Bornet A. A scoping review of artificial intelligence applications in clinical trial risk assessment. *NPJ Digit Med*. 2025;8:486. doi:10.1038/s41746-025-01886-7 PMC
67. Investigation and evaluation of randomized controlled trials for interventions involving artificial intelligence. *Intelligent Medicine*. 2021;1:100006. doi:10.1016/j.imed.2021.04.006
68. Du P, Fan R, Zhang N, Wu C, Zhang Y. Advances in Integrated Multi-omics Analysis for Drug-Target Identification. *Biomolecules*. 2024;14(6):692. doi:10.3390/biom14060692 MDPI
69. Qi X, Zhao Y, Qi Z, Hou S, Chen J. Machine Learning Empowering Drug Discovery: Applications, Opportunities and Challenges. *Molecules*. 2024;29(4):903. doi:10.3390/molecules29040903 MDPI
70. Ali N, Hanif N, Khan H.A, et al. Deep learning and artificial intelligence for drug discovery, application, challenge, and future perspectives. *Discover Applied Sciences*. 2025;7:533. doi:10.1007/s42452-025-06991-6 SpringerLink
71. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. *Drugs and Drug Candidates*. 2024;3(1):148-171. doi:10.3390/ddc3010009 MDPI
72. Guo S, Zhang D, Wang H, An Q, Yu G, Han J, Jiang C, Huang J. Computational and systematic analysis of multi-omics data for drug discovery and development. *Frontiers in Medicine*. 2023;10:1146896. doi:10.3389/fmed.2023.1146896 Frontiers
73. Ali N, Hanif N, Khan H.A, et al. (same as #3) — included to note its relevance across multiple topics.
74. "Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers." *Proteomes*. 2023;11(4):34. doi:10.3390/proteomes11040034 MDPI
75. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review. *BioData Mining*. 2025;??(??):??. doi:10.1186/s13040-025-00442-z BioMed Central

76. "Transforming Clinical Research: The Power of High-Throughput Omics Integration." *Proteomes*. 2024;12(3):25. doi:10.3390/proteomes12030025
77. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. *Discover Pharmaceutical Sciences*. 2025;1:7. doi:10.1007/s44395-025-00007-3 SpringerLink
78. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. *Drugs and Drug Candidates*. 2024;3(1):148-171. doi:10.3390/ddc3010009 MDPI
79. Advances in Integrated Multi-omics Analysis for Drug-Target Identification. *Biomolecules*. 2024;14(6):692. doi:10.3390/biom14060692 MDPI+1
80. The Impact of Artificial Intelligence on Drug Discovery; A Comprehensive Review. *Asian Journal of Pharmaceutical Research and Development*. 2024;12(2):171-178. doi:10.22270/ajprd.v11i3.1230 Ajprd
81. Advances in Artificial Intelligence for Drug Discovery and Development: A Review of Current Trends and Applications. *Asian Journal of Pharmaceutical Research and Development*. 2025;13(2):67-78. doi:10.22270/ajprd.v13i2.1541 Ajprd
82. Emerging of Artificial Intelligence and Technology in Pharmaceuticals: Review. *Future Journal of Pharmaceutical Sciences*. 2023;9:65. doi:10.1186/s43094-023-00517-w SpringerLink
83. Thinking on the Use of Artificial Intelligence in Drug Discovery. *J Med Chem*. 2025;68(5):4996-4999. doi:10.1021/acs.jmedchem.5c00373 American Chemical Society Publications
84. AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors. *ACS Med Chem Lett*. 2024;15(3):334-336. doi:10.1021/acsmedchemlett.4c00057 American Chemical Society Publications
85. Editorial: Artificial intelligence and machine learning for drug discovery, design and repurposing: methods and applications. *Front Pharmacol*. 2023;14:1333747. doi:10.3389/fphar.2023.1333747 Frontiers
86. Editorial: Utilizing omics strategies to discover new drug targets for cancers. *Front Pharmacol*. 2024;15:1526976. doi:10.3389/fphar.2024.1526976
87. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18(6):463–77. doi:10.1038/s41573-019-0024-5
88. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discov Today*. 2018;23(6):1241–50. doi:10.1016/j.drudis.2018.01.03
89. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. *Nat Mach Intell*. 2020;2:573–84. doi:10.1038/s42256-020-00236-4
90. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80–93. doi:10.1016/j.drudis.2020.10.01

91. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol*. 2019;37(9):1038–40. doi:10.1038/s41587-019-0224-x
92. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell*. 2020;180(4):688–702.e13. doi:10.1016/j.cell.2020.01.021
93. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596:583–9. doi:10.1038/s41586-021-03819-2
94. Lavecchia A. Deep learning in drug discovery: opportunities, challenges and future prospects. *Drug Discov Today*. 2019;24(10):2017–33. doi:10.1016/j.drudis.2019.07.00
95. Rifaioglu AS, Doğan T, Jesus Martin M, Atalay V. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and datasets. *Brief Bioinform*. 2020;21(5):1878–902. doi:10.1093/bib/bbz158
96. Hasselgren C, Schuler J, Bender A. Artificial Intelligence in Drug Discovery: Are We There Yet? *Annu Rev Pharmacol Toxicol*. 2024;64:527–50. doi:10.1146/annurev-pharmtox-040323-040828
97. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. *Drugs and Drug Candidates*. 2024;3(1):148-171. doi:10.3390/ddc3010009 MDPI
98. Stegmann JU, Littlebury R, Trengove M, et al. Trustworthy AI for safe medicines. *Nature Reviews Drug Discovery*. 2023;22:855-856. doi:10.1038/s41573-023-00769-4 Nature
99. Khan MK, Raza M, Shahbaz M, Hussain I, Khan MF, Xie Z, Shah SSA, Tareen AK, Bashir Z, Khan K. The recent advances in the approach of artificial intelligence (AI) towards drug discovery. *Frontiers in Chemistry*. 2024;12:1408740. doi:10.3389/fchem.2024.1408740
100. Satinder Singh, Vyas Shingatgeri, Pratima Srivastava. Revolutionizing new drug discovery: Harnessing AI and machine learning to overcome traditional challenges and accelerate targeted therapies. *AI Health (AIH)*. 2025;2(2):29-40. doi:10.36922/aih.4423